MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake’s nanobody drug shows promise in treating psoriatic arthritis, but investors are cautious.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 14.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
Source diversity sample: marketscreener.com · Dermatology Times · Kalkine Media · FirstWord Pharma · Fierce Biotech.
How this dossier is built: methodology · AI policy · corrections.
Who reported it (5)
- MoonLake's psoriatic arthritis drug meets key goals in late-stage trial marketscreener.com · 7h ago
- Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial Dermatology Times · 7h ago
- MoonLake Immunotherapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Cash Reserves Kalkine Media · 7h ago
- MoonLake touts Phase III PsA data, but investors may have wanted more FirstWord Pharma · 7h ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial Fierce Biotech · 7h ago
What happened
MoonLake Immunotherapeutics announced today that its nanobody drug, sonelokimab, has met all clinical endpoints in a phase 3 trial for psoriatic arthritis. The trial results indicate that the drug has achieved its primary goal, demonstrating efficacy in treating the condition. The news comes as MoonLake also released its Q2 2026 financial results, which show an increased net loss despite higher cash reserves.
The success of sonelokimab in the phase 3 trial is significant. According to Fierce Biotech and Dermatology Times, the drug has boosted all clinical endpoints, suggesting it could be a valuable addition to the treatment options for psoriatic arthritis. However, FirstWord Pharma notes that investors may have anticipated more robust results, indicating a potential gap between the clinical success and market expectations.
The financial performance of MoonLake adds another layer of complexity. The increased net loss, as detailed by marketscreener.com and Kalkine Media, suggests that while the drug shows promise, the company faces financial challenges. This financial context may influence investor sentiment and the drug's path to market.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 2h ago.
Questions people are asking
What is sonelokimab?
Sonelokimab is a nanobody drug developed by MoonLake Immunotherapeutics for the treatment of psoriatic arthritis.
What were the results of the phase 3 trial?
The phase 3 trial results indicate that sonelokimab met all clinical endpoints, demonstrating efficacy in treating psoriatic arthritis.
How did MoonLake perform financially in Q2 2026?
MoonLake reported an increased net loss for Q2 2026, despite having higher cash reserves.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer's Phase 3 trial for the lung cancer drug Sigvotatug Vedotin failed to meet its primary endpoint for survival.
Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says
Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.